{"id":50483,"date":"2022-11-04T00:02:33","date_gmt":"2022-11-03T23:02:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/"},"modified":"2022-11-04T00:02:33","modified_gmt":"2022-11-03T23:02:33","slug":"nhc-reports-third-quarter-2022-earnings","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/","title":{"rendered":"NHC Reports Third Quarter 2022 Earnings"},"content":{"rendered":"
\n

MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation<\/a> (NYSE American: NHC<\/a>), the nation’s oldest publicly traded senior health care company, announced today net operating revenues and government stimulus income for the quarter ended September 30, 2022 totaled $270,843,000 compared to $276,737,000 for the quarter ended September 30, 2021, a decrease of 2.1%. The net operating revenues decrease during the third quarter of 2022 was primarily driven by the reduction in government stimulus income of $10.4 million during the third quarter of 2022 compared to the same period a year ago, as well as us exiting the seven skilled nursing facilities in Massachusetts and New Hampshire during the third quarter of 2022. Excluding the government stimulus income, same-facility net operating revenues increased 3.8% during the third quarter of 2022 compared to the same period a year ago.\n<\/p>\n

<\/a><\/p>\n

\nFor the quarter ended September 30, 2022, the reported GAAP net loss attributable to NHC was $2,429,000 compared to a net loss of $3,348,000 for the same period in 2021. Excluding the unrealized losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended September 30, 2022 was $7,783,000 compared to $14,884,000 for the same period in 2021 (*)<\/sup>. The decrease in non-GAAP earnings for the third quarter of 2022 compared to the same period in 2021 was primarily due to the $10.4 million less of government stimulus income recorded, as well as incurring inflationary wage pressures on our labor costs. GAAP diluted loss per share was $0.16 for the quarter ended September 30, 2022 compared to a diluted loss per share of $0.22 for the same period in 2021. Adjusted diluted earnings per share were $0.50 and $0.96 for the quarters ended September 30, 2022 and 2021, respectively (*)<\/sup>.\n<\/p>\n

\n(*) – See the tables below that provide a reconciliation of GAAP to non-GAAP items.\n<\/p>\n

\nAbout NHC<\/b>\n<\/p>\n

\nNHC affiliates operate for themselves and third parties 68 skilled nursing facilities with 8,726 beds. NHC affiliates also operate 23 assisted living communities with 1,181 units, five independent living communities with 475 units, three behavioral health hospitals, 35 homecare agencies, and 29 hospice agencies. NHC\u2019s other services include Alzheimer\u2019s and memory care units, pharmacy services, a rehabilitation services company, and providing management and accounting services to third party post-acute operators. Other information about the company can be found on our web site at www.nhccare.com<\/a>.\n<\/p>\n

\nNon-GAAP Financial Presentation<\/b>\n<\/p>\n

\nThe Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company\u2019s operations and measure the Company\u2019s performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nStatements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q and 10-K, and include, among others, the following: liabilities and other claims asserted against us and patient care liabilities, as well as the resolution of current litigation; availability of insurance and assets for indemnification; national and local economic conditions; including their effect on the availability and cost of labor, utilities and materials; the effect of government regulations and changes in regulations governing the healthcare industry, including our compliance with such regulations; changes in Medicare and Medicaid payment levels and methodologies and the application of such methodologies by the government and its fiscal intermediaries; and other factors referenced or incorporated by reference in the S.E.C. filings. The risks included here are not exhaustive. All forward-looking statements represent NHC\u2019s best judgment as of the date of this release.\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Consolidated Statements of Operations<\/b><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
(in thousands, except share and per share amounts)<\/i><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\nThree Months Ended<\/td>\n<\/td>\nNine Months Ended<\/td>\n<\/tr>\n
<\/td>\nSeptember 30<\/td>\n<\/td>\nSeptember 30<\/td>\n<\/tr>\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n(unaudited)<\/i><\/td>\n<\/td>\n(unaudited)<\/i><\/td>\n<\/tr>\n
Revenues and grant income:<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Net patient revenues<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n260,247<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n254,817\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n776,661<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n708,648\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Other revenues<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,596<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,491\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n33,584<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n33,916\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Government stimulus income<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,429\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,940<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n48,304\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Net operating revenues and grant income<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n270,843<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n276,737\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n821,185<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n790,868\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Costs and expenses:<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Salaries, wages and benefits<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n173,198<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n170,235\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n518,828<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n483,263\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Other operating<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n72,883<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n73,109\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n218,279<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n204,211\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Facility rent<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,294<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,204\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n30,770<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n30,437\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Depreciation and amortization<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,253<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,229\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n30,011<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n30,521\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Interest<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n137<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n198\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n451<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n657\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Total costs and expenses<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n266,765<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n263,975\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n798,339<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n749,089\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Income from operations<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,078<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n12,762\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n22,846<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n41,779\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-operating income<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,731<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,399\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n8,451<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,245\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Gain on acquisition of equity method investment<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n95,202\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Unrealized losses on marketable equity securities<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(11,056<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(23,797\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(11,479<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(23,227\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Income\/(loss) before income taxes<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(4,247<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(7,636\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n19,818<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n128,999\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Income tax (provision)\/benefit<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,140<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,090\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(5,415<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(5,907\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

Net income\/(loss)<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(3,107<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(3,546\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n14,403<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n123,092\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net (income)\/loss attributable to noncontrolling interest<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n678<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n198\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,689<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(290\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net income\/(loss) attributable to National HealthCare Corporation<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n(2,429<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(3,348\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n16,092<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n122,802\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net income\/(loss) per common share<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Basic<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n(0.16<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(0.22\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n1.04<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n8.00\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Diluted<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n(0.16<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(0.22\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n1.04<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n7.97\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Weighted average common shares outstanding<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Basic<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,445,569<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,364,043\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,438,375<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,347,042\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Diluted<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,445,569<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,364,043\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n14,577,103<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,414,683\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Dividends declared per common share<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n0.57<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n0.52\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n1.69<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n1.56\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Balance Sheet Data<\/b><\/td>\nSept. 30<\/b><\/td>\n<\/td>\nDec. 31<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
(in thousands)<\/i><\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2021\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n(unaudited)<\/i><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Cash, cash equivalents and marketable securities<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n176,729<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n256,025\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Restricted cash, cash equivalents and marketable securities<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n171,898<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n175,884\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Current assets<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n344,529<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n426,638\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Property and equipment, net<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n511,373<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n520,996\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Total assets<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,295,559<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,403,396\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Current liabilities<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n210,156<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n263,201\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
NHC stockholders’ equity<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n877,311<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n903,004\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Selected Operating Statistics<\/b><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\nThree Months Ended<\/td>\n<\/td>\nNine Months Ended<\/td>\n<\/tr>\n
<\/td>\nSeptember 30<\/td>\n<\/td>\nSeptember 30<\/td>\n<\/tr>\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n(unaudited)<\/i><\/td>\n<\/td>\n(unaudited)<\/i><\/td>\n<\/tr>\n
Skilled Nursing Per Diems:<\/b><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Medicare<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n535.60<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n523.98\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n540.30<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n528.60\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Managed Care<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n429.22<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n404.43\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n425.39<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n406.32\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Medicaid<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n237.61<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n231.39\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n230.79<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n225.68\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Private Pay and Other<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n265.68<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n257.13\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n268.13<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n254.03\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Average Skilled Nursing Per Diem<\/b><\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n302.43<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n295.40\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n301.91<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n297.04\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Skilled Nursing Patient Days:<\/b><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Medicare<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n81,940<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n87,534\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n258,961<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n271,024\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Managed Care<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n52,956<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n57,486\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n163,823<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n183,593\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Medicaid<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n302,500<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n315,979\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n919,931<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n895,955\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Private Pay and Other<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n169,068<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n158,011\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n489,477<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n439,225\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Total Skilled Nursing Patient Days<\/b><\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n606,464<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n619,010\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,832,192<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,789,797\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
The tables below provide reconciliations of GAAP to non-GAAP items (in thousands, except per share amounts):<\/td>\n<\/tr>\n
<\/td>\n<\/tr>\n
<\/td>\nThree Months Ended<\/td>\n<\/td>\nNine Months Ended<\/td>\n<\/tr>\n
<\/td>\nSeptember 30<\/td>\n<\/td>\nSeptember 30<\/td>\n<\/tr>\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n(unaudited)<\/i><\/td>\n<\/td>\n(unaudited)<\/i><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net income\/(loss) attributable to National Healthcare Corporation<\/b><\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n(2,429<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(3,348\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n16,092<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n122,802\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Non-GAAP adjustments<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Unrealized losses on marketable equity securities<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,056<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n23,797\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,479<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n23,227\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Operating results for newly opened facilities not at full capacity (1)<\/sup><\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,105<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n115\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,033<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n480\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Gain on acquisition of equity method investment<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(95,202\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

Stock-based compensation expense<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n639<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n726\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,980<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,905\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Income tax benefit on non-GAAP adjustments<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(3,588<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(6,406\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(4,548<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(6,369\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

Non-GAAP Net income<\/b><\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n7,783<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n14,884\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n29,036<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n46,843\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
GAAP diluted earnings\/(loss) per share<\/b><\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n(0.16<\/b>\n<\/p>\n<\/td>\n

\n

\n)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(0.22\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n1.04<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n7.97\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Non-GAAP adjustments<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Unrealized losses on marketable equity securities<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.53<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1.14\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.56<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1.12\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Operating results for newly opened facilities not at full capacity (1)<\/sup><\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.10<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.01\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.19<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.02\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Gain on acquisition of equity method investment<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n–<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(6.16\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

Stock-based compensation expense<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.03<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.03\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.09<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.09\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

Non-GAAP diluted earnings per share<\/b><\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n0.50<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n0.96\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/b>\n<\/p>\n<\/td>\n

\n

\n1.88<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n3.04\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
(1)<\/sup> The newly opened facilities not at full capacity for the 2022 period presented consisted of operations opened from 2020 through 2022. This consisted of two behavioral health hospitals, one homecare agency, and one hospice agency. The newly opened facilities for the 2021 period presented consisted of operations opened from 2019 through 2021. The 2021 period consisted of one memory care facility.<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBrian F. Kidd, SVP\/Controller
\n
Phone: (615) 890-2020\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded senior health care company, announced today net operating revenues and government stimulus income for the quarter ended September 30, 2022 totaled $270,843,000 compared to $276,737,000 for the quarter ended September 30, 2021, a decrease of 2.1%. The net operating revenues decrease during … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50483","6":"format-standard","7":"category-industry"},"yoast_head":"\nNHC Reports Third Quarter 2022 Earnings - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHC Reports Third Quarter 2022 Earnings - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded senior health care company, announced today net operating revenues and government stimulus income for the quarter ended September 30, 2022 totaled $270,843,000 compared to $276,737,000 for the quarter ended September 30, 2021, a decrease of 2.1%. The net operating revenues decrease during ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-03T23:02:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221103006385\/en\/672611\/21\/NHC_Corp_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NHC Reports Third Quarter 2022 Earnings\",\"datePublished\":\"2022-11-03T23:02:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/\"},\"wordCount\":1029,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006385\\\/en\\\/672611\\\/21\\\/NHC_Corp_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/\",\"name\":\"NHC Reports Third Quarter 2022 Earnings - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006385\\\/en\\\/672611\\\/21\\\/NHC_Corp_logo.jpg\",\"datePublished\":\"2022-11-03T23:02:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006385\\\/en\\\/672611\\\/21\\\/NHC_Corp_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006385\\\/en\\\/672611\\\/21\\\/NHC_Corp_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nhc-reports-third-quarter-2022-earnings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHC Reports Third Quarter 2022 Earnings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NHC Reports Third Quarter 2022 Earnings - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/","og_locale":"en_US","og_type":"article","og_title":"NHC Reports Third Quarter 2022 Earnings - Pharma Trend","og_description":"MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded senior health care company, announced today net operating revenues and government stimulus income for the quarter ended September 30, 2022 totaled $270,843,000 compared to $276,737,000 for the quarter ended September 30, 2021, a decrease of 2.1%. The net operating revenues decrease during ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-03T23:02:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221103006385\/en\/672611\/21\/NHC_Corp_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NHC Reports Third Quarter 2022 Earnings","datePublished":"2022-11-03T23:02:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/"},"wordCount":1029,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103006385\/en\/672611\/21\/NHC_Corp_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/","url":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/","name":"NHC Reports Third Quarter 2022 Earnings - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103006385\/en\/672611\/21\/NHC_Corp_logo.jpg","datePublished":"2022-11-03T23:02:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221103006385\/en\/672611\/21\/NHC_Corp_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221103006385\/en\/672611\/21\/NHC_Corp_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nhc-reports-third-quarter-2022-earnings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NHC Reports Third Quarter 2022 Earnings"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50483"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50483\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}